(Alliance News) - Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form business. Denmark-based Xellia Pharmaceuticals ApS. Xellia's FDF ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

U.S sterile injectables market is estimated to be valued at US$ 131.8 billion in 2022 and expected to exhibit a CAGR of 9.3% over the forecast period 2022-2030 ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Tahaluf, Saudi Arabia’s fastest-growing business event organiser, has launched the latest in its vertical industry shows - CPHI Middle East, the region’s premier pharmaceutical event - marking a ...